JP2006504822A - 糖と結合する表面 - Google Patents
糖と結合する表面 Download PDFInfo
- Publication number
- JP2006504822A JP2006504822A JP2004547780A JP2004547780A JP2006504822A JP 2006504822 A JP2006504822 A JP 2006504822A JP 2004547780 A JP2004547780 A JP 2004547780A JP 2004547780 A JP2004547780 A JP 2004547780A JP 2006504822 A JP2006504822 A JP 2006504822A
- Authority
- JP
- Japan
- Prior art keywords
- plasma
- carbohydrate
- monomer
- polymer
- obtainable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000000346 sugar Nutrition 0.000 title description 11
- 238000000034 method Methods 0.000 claims abstract description 87
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 66
- 239000000178 monomer Substances 0.000 claims abstract description 48
- 229920000642 polymer Polymers 0.000 claims abstract description 46
- 230000003100 immobilizing effect Effects 0.000 claims abstract description 11
- 239000011248 coating agent Substances 0.000 claims abstract description 4
- 238000000576 coating method Methods 0.000 claims abstract description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 28
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 24
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical group NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 claims description 22
- 238000006116 polymerization reaction Methods 0.000 claims description 21
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 15
- 229920000669 heparin Polymers 0.000 claims description 15
- 229960002897 heparin Drugs 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 150000001412 amines Chemical class 0.000 claims description 12
- 229930195733 hydrocarbon Natural products 0.000 claims description 11
- 150000002430 hydrocarbons Chemical class 0.000 claims description 11
- 239000004215 Carbon black (E152) Substances 0.000 claims description 9
- 150000001336 alkenes Chemical class 0.000 claims description 9
- 239000011159 matrix material Substances 0.000 claims description 7
- 239000000523 sample Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 238000002493 microarray Methods 0.000 claims description 6
- 229920002971 Heparan sulfate Polymers 0.000 claims description 5
- 238000001261 affinity purification Methods 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 3
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 3
- 229920000869 Homopolysaccharide Polymers 0.000 claims description 3
- 229920000288 Keratan sulfate Polymers 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 3
- 229940051593 dermatan sulfate Drugs 0.000 claims description 3
- 150000001993 dienes Chemical class 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims description 3
- 229940099552 hyaluronan Drugs 0.000 claims description 3
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 150000001345 alkine derivatives Chemical class 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 description 54
- 230000027455 binding Effects 0.000 description 19
- 239000007789 gas Substances 0.000 description 16
- 150000004676 glycans Chemical class 0.000 description 16
- 229920001282 polysaccharide Polymers 0.000 description 16
- 239000005017 polysaccharide Substances 0.000 description 16
- 239000000126 substance Substances 0.000 description 13
- 125000000524 functional group Chemical group 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000001179 sorption measurement Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 150000008163 sugars Chemical class 0.000 description 8
- -1 aminomethyl fluorescein Chemical compound 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000010408 film Substances 0.000 description 5
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Chemical class NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000007334 copolymerization reaction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 229920006254 polymer film Polymers 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QTYUSOHYEPOHLV-FNORWQNLSA-N 1,3-Octadiene Chemical compound CCCC\C=C\C=C QTYUSOHYEPOHLV-FNORWQNLSA-N 0.000 description 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WJYIASZWHGOTOU-UHFFFAOYSA-N Heptylamine Chemical compound CCCCCCCN WJYIASZWHGOTOU-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-N alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-VCSGLWQLSA-N alpha-L-iduronic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-VCSGLWQLSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N beta-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 150000002016 disaccharides Chemical group 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000012855 volatile organic compound Substances 0.000 description 2
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical class N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- WIFSDCDETBPLOR-UHFFFAOYSA-N 2-aminobenzoic acid Chemical compound NC1=CC=CC=C1C(O)=O.NC1=CC=CC=C1C(O)=O WIFSDCDETBPLOR-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101000847156 Homo sapiens Tumor necrosis factor-inducible gene 6 protein Proteins 0.000 description 1
- OVRNDRQMDRJTHS-PVFLNQBWSA-N N-acetyl-alpha-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-PVFLNQBWSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate group Chemical group [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- PGFXOWRDDHCDTE-UHFFFAOYSA-N hexafluoropropylene oxide Chemical compound FC(F)(F)C1(F)OC1(F)F PGFXOWRDDHCDTE-UHFFFAOYSA-N 0.000 description 1
- 102000050255 human TNFAIP6 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 229960004624 perflexane Drugs 0.000 description 1
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229920000083 poly(allylamine) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- ZNZJJSYHZBXQSM-UHFFFAOYSA-N propane-2,2-diamine Chemical compound CC(C)(N)N ZNZJJSYHZBXQSM-UHFFFAOYSA-N 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 230000003075 superhydrophobic effect Effects 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/548—Carbohydrates, e.g. dextran
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Materials For Medical Uses (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Prostheses (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
i)単量体源を準備し、
ii)前記単量体のプラズマを生じさせ、
iii)ある表面を前記プラズマで被覆することでプラズマ重合体で被覆された表面を生じさせ、そして
iv)前記重合体で被覆された表面を少なくとも1種の炭水化物分子と接触させることで、前記重合体で被覆された表面に前記炭水化物分子を受動的に吸着させる、
段階を含んで成る。
プラズマ重合
アリルアミンを単量体として用いたプラズマ重合を96穴ミクロタイター上で実施した。流量を1−5cm3 stp分−1にしかつ反応槽の圧力を約2x10−2ミリバールにして10W未満のRF(13.56MHz)電力を用いた。付着させた膜の化学的性質をX線光電子分光法(XPS)で分析した。そのプラズマ装置の図式図を図1に示す。
ヘパリンの吸着
PBSに由来するヘパリンを室温でアリルアミン被覆部分および未被覆部分(製造業者独自の処理)の両方に一晩吸着させた。標準的ELISA方法に従って、結合しなかったヘパリンを表面から洗い流した後、結合している残りの分子をビオチニル化検出用分子(即ちヒトTSG−6に由来するリンクモジュール)[Mahoney他、J.Biol.Chem.276、22764−22771(2001);Parkar & Day FEBS Lett.410、413−417(1997)]を用いて検出した。
Claims (32)
- 少なくとも1種の炭水化物分子を固定する方法であって、
i)単量体源を準備し、
ii)前記単量体のプラズマを生じさせ、
iii)ある表面を前記プラズマで被覆することでプラズマ重合体で被覆された表面を生じさせ、そして
iv)前記重合体で被覆された表面を未変性形態の少なくとも1種の炭水化物分子と接触させる、
段階を含んで成る方法。 - 前記炭水化物を前記プラズマ重合体で被覆された表面に受動的に吸着させる請求項1記載の方法。
- 前記炭水化物を少なくとも1種の炭水化物分子が入っている溶液として供給する請求項1または2記載の方法。
- 前記単量体が揮発性アルコールである請求項1から3のいずれか記載の方法。
- 前記単量体が揮発性アミンである請求項1から3のいずれか記載の方法。
- 前記単量体が揮発性炭水化物である請求項1から3のいずれか記載の方法。
- 前記単量体が揮発性酸である請求項1から3のいずれか記載の方法。
- 前記表面が窒素含有量が少なくとも2%の重合体を含んで成る前請求項のいずれか記載の方法。
- 前記窒素含有量が2−20%である請求項8記載の方法。
- 前記表面が窒素含有量が20%を超える重合体を含んで成る請求項1から7のいずれか記載の方法。
- 前記単量体がヒドロキシル、アミノまたはカルボン酸基を含有する請求項1、2または3記載の方法。
- 前記単量体がアリルアミンである請求項10記載の方法。
- 前記単量体が周囲の室温で少なくとも6.6x10−2ミリバールの蒸気圧を示す前請求項のいずれか記載の方法。
- 前記プラズマ重合体をW/FMが<109J/kg、理想的には<108J/kg、より理想的には<107J/kgのプラズマから付着させる前請求項のいずれか記載の方法。
- 前記重合体がアミン共重合体を含んで成る請求項1から3のいずれか記載の方法。
- 前記共重合体を有機アミンと炭素数が20以下の飽和(アルカン)もしくは不飽和(アルケン、ジエンまたはアルキン)炭化水素のプラズマ重合で生じさせる請求項15記載の方法。
- 前記炭水化物がホモ多糖である前請求項のいずれか記載の方法
- 前記炭水化物がヘテロ多糖である請求項1から16のいずれか記載の方法
- 前記ヘテロ多糖がグリコサミノグリカンである請求項18記載の方法
- 前記グリコサミノグリカンをヒアルロナン、デルマタン硫酸、コンドロイチン硫酸、ヘパリン、ヘパラン硫酸またはケラタン硫酸から成る群から選択する請求項19記載の方法
- 前記表面がバイオセンサーの一部である前請求項のいずれか記載の方法。
- 前記表面が治療媒体の一部である請求項1から20のいずれか記載の方法。
- 前記表面が生物学的サンプルを動物、好適にはヒトから採集する時に用いられる機器の一部である請求項1から20のいずれか記載の方法。
- 前記表面がアフィニティー精製用マトリックスの一部である請求項1から20のいずれか記載の方法。
- 前記表面がマイクロアレイの一部である請求項1から20のいずれか記載の方法。
- 請求項1から20のいずれか記載の方法で入手可能な表面を含んで成るバイオセンサー。
- 請求項1から20のいずれか記載の方法で入手可能な表面を含んで成る治療媒体。
- 請求項1から20のいずれか記載の方法で入手可能な表面を含んで成るサンプル採集用機器。
- 請求項1から20のいずれか記載の方法で入手可能な表面を含んで成るアフィニティー精製用マトリックス。
- 請求項1から20のいずれか記載の方法で入手可能な表面を含んで成るマイクロアレイ。
- プラズマ重合で入手可能な表面であって、未変性形態の少なくとも1種の炭水化物分子を固定する表面。
- 前記炭水化物分子を受動的に吸着する請求項31記載の表面。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0225197.3 | 2002-10-30 | ||
GBGB0225197.3A GB0225197D0 (en) | 2002-10-30 | 2002-10-30 | Surface |
PCT/GB2003/004653 WO2004040308A1 (en) | 2002-10-30 | 2003-10-29 | Sugar binding surface |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006504822A true JP2006504822A (ja) | 2006-02-09 |
JP5153995B2 JP5153995B2 (ja) | 2013-02-27 |
Family
ID=9946825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004547780A Expired - Fee Related JP5153995B2 (ja) | 2002-10-30 | 2003-10-29 | 糖と結合する表面 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060251693A1 (ja) |
EP (1) | EP1556696B1 (ja) |
JP (1) | JP5153995B2 (ja) |
CN (1) | CN100475363C (ja) |
AU (1) | AU2003301706B2 (ja) |
CA (1) | CA2542354C (ja) |
GB (1) | GB0225197D0 (ja) |
NZ (1) | NZ539224A (ja) |
WO (1) | WO2004040308A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010029186A (ja) * | 2008-07-25 | 2010-02-12 | Becton Dickinson & Co | 規定細胞培養表面及び使用方法 |
JP2010526291A (ja) * | 2007-05-04 | 2010-07-29 | クラロス ダイアグノスティクス, インコーポレイテッド | 流体コネクタおよびマイクロ流体システム |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7148343B2 (en) * | 2001-10-12 | 2006-12-12 | Gentra Systems, Inc. | Compositions and methods for using a solid support to purify RNA |
GB0408351D0 (en) * | 2004-04-15 | 2004-05-19 | Plasso Technology Ltd | Reversible binding surface |
WO2006002382A2 (en) * | 2004-06-24 | 2006-01-05 | The Scripps Research Institute | Arrays with cleavable linkers |
CN101124321B (zh) | 2004-11-05 | 2012-02-29 | 恰根北美控股有限公司 | 用于从稳定剂中纯化核酸的组合物和方法 |
US8288118B2 (en) | 2007-09-19 | 2012-10-16 | Becton, Dickinson And Company | Method of analyzing various surface chemistries for culturing a given cell line |
US8802603B2 (en) | 2010-06-17 | 2014-08-12 | Becton, Dickinson And Company | Medical components having coated surfaces exhibiting low friction and low reactivity |
GB2528856A (en) * | 2014-07-31 | 2016-02-10 | P2I Ltd | Binding surfaces |
GB201513097D0 (en) | 2015-07-24 | 2015-09-09 | Univ Sheffield | Medical implant |
FR3039548B1 (fr) * | 2015-07-30 | 2019-05-31 | Centre National De La Recherche Scientifique (C.N.R.S) | Nouveau procede de polymerisation de sucres |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05220217A (ja) * | 1991-05-21 | 1993-08-31 | Hewlett Packard Co <Hp> | 医療デバイスの表面処理方法及びその装置 |
WO1994010938A1 (en) * | 1992-11-19 | 1994-05-26 | Case Western Reserve University | Anticoagulant plasma polymer-modified substrate |
WO2002060509A1 (en) * | 2001-01-31 | 2002-08-08 | Percardia, Inc. | Methods for surface modification |
JP2002531183A (ja) * | 1998-12-03 | 2002-09-24 | ボストン サイエンティフィック リミテッド | 活性剤の制御された送達のためのポリマーコーティング |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4326532A (en) * | 1980-10-06 | 1982-04-27 | Minnesota Mining And Manufacturing Company | Antithrombogenic articles |
US4362532A (en) * | 1981-08-11 | 1982-12-07 | Conoco Inc. | Production of blast furnace coke via novel briquetting system |
CA1215676A (en) * | 1983-04-27 | 1986-12-23 | Terry S. Dunn | Heparinization of plasma treated substrates |
US4632842A (en) * | 1985-06-20 | 1986-12-30 | Atrium Medical Corporation | Glow discharge process for producing implantable devices |
JP2681653B2 (ja) * | 1988-05-13 | 1997-11-26 | 台糖株式会社 | 抗エイズウィルス剤 |
US5262451A (en) * | 1988-06-08 | 1993-11-16 | Cardiopulmonics, Inc. | Multifunctional thrombo-resistant coatings and methods of manufacture |
US4865870A (en) * | 1988-07-07 | 1989-09-12 | Becton, Dickinson And Company | Method for rendering a substrate surface antithrombogenic |
US5571166A (en) * | 1992-03-19 | 1996-11-05 | Medtronic, Inc. | Method of making an intraluminal stent |
SE9301270D0 (sv) * | 1993-04-19 | 1993-04-17 | Biosensor | |
US6022602A (en) * | 1994-01-26 | 2000-02-08 | Neomecs Incorporated | Plasma modification of lumen surface of tubing |
US5925552A (en) * | 1996-04-25 | 1999-07-20 | Medtronic, Inc. | Method for attachment of biomolecules to medical devices surfaces |
US6077232A (en) * | 1996-12-27 | 2000-06-20 | Sherwood Services Ag | Anticoagulant composition |
US6776792B1 (en) * | 1997-04-24 | 2004-08-17 | Advanced Cardiovascular Systems Inc. | Coated endovascular stent |
US5876730A (en) * | 1997-08-07 | 1999-03-02 | Childrens Hospital Research Foundation | Heparin-binding growth factor (HBGF) polypeptides |
US6159531A (en) * | 1999-08-30 | 2000-12-12 | Cardiovasc, Inc. | Coating having biological activity and medical implant having surface carrying the same and method |
GB9925016D0 (en) * | 1999-10-23 | 1999-12-22 | Univ Sheffield | Binding surface |
US6613432B2 (en) * | 1999-12-22 | 2003-09-02 | Biosurface Engineering Technologies, Inc. | Plasma-deposited coatings, devices and methods |
US20020098513A1 (en) * | 2000-02-17 | 2002-07-25 | Glycominds Ltd. | Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof |
WO2003030958A1 (en) * | 2001-10-06 | 2003-04-17 | Celltran Limited | Corneal graft |
-
2002
- 2002-10-30 GB GBGB0225197.3A patent/GB0225197D0/en not_active Ceased
-
2003
- 2003-10-29 NZ NZ539224A patent/NZ539224A/en not_active IP Right Cessation
- 2003-10-29 CN CNB2003801024554A patent/CN100475363C/zh not_active Expired - Fee Related
- 2003-10-29 WO PCT/GB2003/004653 patent/WO2004040308A1/en active Application Filing
- 2003-10-29 JP JP2004547780A patent/JP5153995B2/ja not_active Expired - Fee Related
- 2003-10-29 AU AU2003301706A patent/AU2003301706B2/en not_active Expired
- 2003-10-29 CA CA2542354A patent/CA2542354C/en not_active Expired - Fee Related
- 2003-10-29 US US10/533,063 patent/US20060251693A1/en not_active Abandoned
- 2003-10-29 EP EP03809772.1A patent/EP1556696B1/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05220217A (ja) * | 1991-05-21 | 1993-08-31 | Hewlett Packard Co <Hp> | 医療デバイスの表面処理方法及びその装置 |
WO1994010938A1 (en) * | 1992-11-19 | 1994-05-26 | Case Western Reserve University | Anticoagulant plasma polymer-modified substrate |
JP2002531183A (ja) * | 1998-12-03 | 2002-09-24 | ボストン サイエンティフィック リミテッド | 活性剤の制御された送達のためのポリマーコーティング |
WO2002060509A1 (en) * | 2001-01-31 | 2002-08-08 | Percardia, Inc. | Methods for surface modification |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010526291A (ja) * | 2007-05-04 | 2010-07-29 | クラロス ダイアグノスティクス, インコーポレイテッド | 流体コネクタおよびマイクロ流体システム |
JP2010029186A (ja) * | 2008-07-25 | 2010-02-12 | Becton Dickinson & Co | 規定細胞培養表面及び使用方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2004040308A1 (en) | 2004-05-13 |
EP1556696A1 (en) | 2005-07-27 |
JP5153995B2 (ja) | 2013-02-27 |
CN1708688A (zh) | 2005-12-14 |
CN100475363C (zh) | 2009-04-08 |
AU2003301706A1 (en) | 2004-05-25 |
CA2542354A1 (en) | 2004-05-13 |
CA2542354C (en) | 2014-04-22 |
AU2003301706B2 (en) | 2009-10-22 |
NZ539224A (en) | 2008-03-28 |
GB0225197D0 (en) | 2002-12-11 |
US20060251693A1 (en) | 2006-11-09 |
EP1556696B1 (en) | 2014-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Peppas | Hydrogels in medicine and pharmacy | |
US5455040A (en) | Anticoagulant plasma polymer-modified substrate | |
JP5153995B2 (ja) | 糖と結合する表面 | |
Seeberger | The logic of automated glycan assembly | |
EP3255085B1 (en) | Ligand graft functionalized substrates | |
Maccarana et al. | Mode of interaction between platelet factor 4 and heparin | |
US5773488A (en) | Hydrophilization of hydrophobic polymers | |
WO1994010938A9 (en) | Anticoagulant plasma polymer-modified substrate | |
JP2005526972A (ja) | 多糖系ヒドロゲルをコーティングした表面を有するバイオチップ | |
EP1735090B1 (en) | Reversible binding surface | |
CN105837730B (zh) | 一种结合层层组装技术和主客体相互作用构建生物活性表面的方法 | |
Yuan et al. | Immobilization of high‐affinity heparin oligosaccharides to radiofrequency plasma‐modified polyethylene | |
Le Pennec et al. | Sweet but Challenging: Tackling the Complexity of GAGs with Engineered Tailor‐Made Biomaterials | |
Szili et al. | Surface modification of biomaterials by plasma polymerization | |
WO2000041739A1 (en) | Attachment of acid moiety-containing biomolecules to activated polymeric surfaces | |
Seeberger | Glycan arrays and other tools produced by automated glycan assembly | |
Hu et al. | Construction of glycosylated surfaces for poly (propylene) beads with a photoinduced grafting/chemical reaction sequence | |
CN110297084A (zh) | 一种生物芯片的抗体高效固定方法 | |
JPH08317785A (ja) | 糖鎖の固定化法及びそれを用いた細胞培養基材 | |
Denes et al. | Immobilization of Active Biopolymers from Cold Plasma–Functionalized Surfaces for the Creation of Molecular Recognition and Molecular Manufacturing Systems | |
JP2833664B2 (ja) | 血液細胞処理剤 | |
JP2834514B2 (ja) | 血液細胞処理剤 | |
Yaseen et al. | Smart thermoresponsive biomaterials | |
JPH0435742A (ja) | β↓2―ミクログロブリン用吸着剤 | |
JP2019018128A (ja) | 糖鎖捕捉性ポリマー粒子 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060728 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20081117 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20081117 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090302 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091106 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100205 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100308 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100409 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100728 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20100729 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100729 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100818 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100910 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20120706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120921 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121005 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121205 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151214 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
LAPS | Cancellation because of no payment of annual fees |